Age of onset is really important when thinking about #MAS Primary HLH more frequent in pediatric population. But can continue to adulthood. #EULAR2025 @RheumNow https://t.co/J7xmTiQiwr

MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP

#infections in #JAKi @drdavidliew #JAKi sl ⬆️ infection risk vs #TNFi ⬆️HZ w JAKi JAKi same risk w #latent #TB #LTBI and new TB ⬇️in JAKi v bDMARDs He didn’t discuss TYK2i Reassuring - risk⬇️ over time for infection @RheumNow #EULAR2025 @eular_org JAKi & infection https://t.co/KVsY2gXVkQ

Management of HLH/MAS and modes of action of advanced therapies Jessica Manson @RheumNow #EULAR2025 https://t.co/Op3u53ZXeK

JAKi: expanding RMD indications—but important safety concerns to consider ⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF ⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi 🗣️ Patients rank infection risk as top concern @rheumnow #EULAR2025 https://t.co/RJRDWQjqNC

Age & dose ⬆️ infections in JAKi Not all JAKi are created w equal risk ⁦@RheumNow⁩ ⁦@eular_org⁩ #EULAR2015 ⁦@drdavidliew⁩ #JAKi & #infection https://t.co/F7zLUBuzJR

Stabilize the pts with HLH with steroids when still trying to figure out the diagnosis of #HLH/ #MAS Many drugs can be used...but important to balance infection risk with immunosuppression These are critical pts. Be vigilant.. #EULAR2025 @RheumNow https://t.co/id4ae3SWtj

3 Fs of diagnosis of #HLH -Fever -Ferritin -Falling blood count Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high! Collaboration between specialists help HLH networks will be helpful like this @RheumNow #EULAR2025 https://t.co/HWbvIma3yx

In #axSpA post #TNFi-IR What to use next? 👇 #ATTRA registry 90% #SpA on #bDMARDs are captured Comparison of TNFi to ▶️ 2nd TNFi vs #IL17i ▶️No diff in #retention ✅better #BASDAI and other outcomes w TNFi! ❎less safety 🤔 #EULAR2025 @RheumNow @eular_org Abst#POS0116 https://t.co/7mqFfD4Amf

#Cancer is not ⬆️in JAKi vs #bDMARDs in #rheumatoid #arthritis When adjusted for #confounders #JAKPOT data Now you see it (unadjusted ⬆️risk) Now you don’t (adjusted =#malignancy) JAKi vs bDMARDs in RA EULAR2025 @RheumNow @eular_org #JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa